Dade Rong

Dade Rong

Auto-generated profile, based on publicly available information

Dade Rong

University of Macau 1 Faculty of Health Sciences, Ministry of Education Frontiers Science Center for Precision Oncology Macau, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2022 in Advanced Science
Verified
Journal Article
Open access
DGDongbo Guo
Dongbo Guo
JLJosh Haipeng Lei
Josh Haipeng Lei
DRDade Rong
Dade Rong
TZTesen Zhang
Tesen Zhang
BZBohan Zhang
Bohan Zhang
SQSongnan Qu
Songnan Qu
Rapid, efficient, and precise cancer therapy is highly desired. Here, this work reports solvothermally synthesized photoactivatable Pt(IV)‐coordinated carbon dots (Pt‐CDs) and their bovine serum albumin (BSA) complex (Pt‐CDs@BSA) as a novel orange light‐triggered anti‐tumor therapeutic agent. The homogeneously distributed Pt(IV) in the Pt‐CDs (Pt: 17.2 wt%) and their carbon cores with significant visible absorption exhibit excellent photocatalytic properties, which not only efficiently releases cytotoxic Pt(II) species but also promotes hydroxy radical generation from water under orange light. When triggered with a 589 nm laser, Pt‐CDs@BSA possesses the ultrastrong cancer cell killing capacities of intracellular Pt(II) species release, hydroxyl radical generation, and acidification, which induce powerful immunogenic cell death. Activation of Pt‐CDs@BSA by a single treatment with a 589 nm laser effectively eliminated the primary tumor and inhibited distant tumor growth and lung metastasis. This study thus presents a new concept for building photoactivatable Pt(IV)‐enriched nanodrug‐based CDs for precision cancer therapy.

1 October 2020 in Cancer Letters
Verified
Journal Article
Closed access
DRDade Rong
Dade Rong
CWChangwei Wang
Changwei Wang
XZXiaomei Zhang
Xiaomei Zhang
YWYanli Wei
Yanli Wei
MZMingming Zhang
Mingming Zhang
HWHaihe Wang
Haihe Wang

15 September 2026
Verified
Other
Open access
HHHanyi He
Hanyi He
YHYangchan Hu
Yangchan Hu
YLYe Lu
Ye Lu
MDMingcong Deng
Mingcong Deng
QBQimei Bao
Qimei Bao
XCXiangdong Cheng
Xiangdong Cheng
Fig. S8 shows RAD51AP1 overexpression restores chemoresistance in PARG-deficient xenografts without toxicity.

15 September 2026
Verified
Other
Open access
HHHanyi He
Hanyi He
YHYangchan Hu
Yangchan Hu
YLYe Lu
Ye Lu
MDMingcong Deng
Mingcong Deng
QBQimei Bao
Qimei Bao
XCXiangdong Cheng
Xiangdong Cheng
Fig. S7 provides biochemical evidence of direct PARG–RAD51AP1 interaction and PAR-dependent ubiquitination.

15 September 2026
Verified
Other
Open access
HHHanyi He
Hanyi He
YHYangchan Hu
Yangchan Hu
YLYe Lu
Ye Lu
MDMingcong Deng
Mingcong Deng
QBQimei Bao
Qimei Bao
XCXiangdong Cheng
Xiangdong Cheng
Fig. S5 shows that PARG deficiency or inhibition exacerbates 5-FU-induced DNA damage.

15 September 2026
Verified
Other
Open access
HHHanyi He
Hanyi He
YHYangchan Hu
Yangchan Hu
YLYe Lu
Ye Lu
MDMingcong Deng
Mingcong Deng
QBQimei Bao
Qimei Bao
XCXiangdong Cheng
Xiangdong Cheng
Fig. S4 shows that capecitabine plus PARG inhibitor treatment is well tolerated in PDX models.